Thus, lncRNA TP73-AS1 silencing may repress the development of HCC and promote radiosensitivity in HCC via the PTEN/Akt signaling pathway, improving HCC therapy [186]. The gene discussed is PTEN; the disease is hepatocellular carcinoma.